|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zong L, Abe M, Seto Y and Ji J: The
challenge of screening for early gastric cancer in China. Lancet.
388:26062016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cervantes A, Roda D, Tarazona N, Roselló S
and Pérez-Fidalgo JA: Current questions for the treatment of
advanced gastric cancer. Cancer Treat Rev. 39:60–67. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Glockzin G and Piso P: Current status and
future directions in gastric cancer with peritoneal dissemination.
Surg Oncol Clin N Am. 21:625–633. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meroni G and Diez-Roux G: TRIM/RBCC, a
novel class of ‘single protein RING finger’ E3 ubiquitin ligases.
Bioessays. 27:1147–1157. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang X, Guo H, Yao B and Helms J: miR-15b
inhibits cancer-initiating cell phenotypes and chemoresistance of
cisplatin by targeting TRIM14 in oral tongue squamous cell cancer.
Oncol Rep. 37:2720–2726. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu G, Guo Y, Xu D, Wang Y, Shen Y, Wang F,
Lv Y, Song F, Jiang D, Zhang Y, et al: TRIM14 regulates cell
proliferation and invasion in osteosarcoma via promotion of the AKT
signaling pathway. Sci Rep. 7:424112017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dong B and Zhang W: High levels of TRIM14
are associated with poor prognosis in hepatocellular carcinoma.
Oncol Res Treat. 41:129–134. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Su X, Wang J, Chen W, Li Z, Fu X and Yang
A: Overexpression of TRIM14 promotes tongue squamous cell carcinoma
aggressiveness by activating the NF-κB signaling pathway.
Oncotarget. 7:9939–9950. 2016.PubMed/NCBI
|
|
11
|
Hu G, Pen W and Wang M: TRIM14 promotes
breast cancer cell proliferation by inhibiting apoptosis. Oncol
Res. Mar 21–2018.(Epub ahead of print). View Article : Google Scholar
|
|
12
|
Hai J, Zhu CQ, Wang T, Organ SL, Shepherd
FA and Tsao MS: TRIM14 is a putative tumor suppressor and regulator
of innate immune response in non-small cell lung cancer. Sci Rep.
7:396922017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu Q, Xiang S, Ma J, Hui P, Wang T, Meng
W, Shi M and Wang Y: Long non-coding RNA CASC15 regulates gastric
cancer cell proliferation, migration and epithelial mesenchymal
transition by targeting CDKN1A and ZEB1. Mol Oncol. 12:799–813.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Z, Dou C, Yao B, Xu M, Ding L, Wang Y,
Jia Y, Li Q, Zhang H, Tu K, et al: Methylation-mediated repression
of microRNA-129-2 suppresses cell aggressiveness by inhibiting high
mobility group box 1 in human hepatocellular carcinoma. Oncotarget.
7:36909–36923. 2016.PubMed/NCBI
|
|
15
|
Chen Y, Liu J, Wang W, Xiang L, Wang J,
Liu S, Zhou H and Guo Z: High expression of hnRNPA1 promotes cell
invasion by inducing EMT in gastric cancer. Oncol Rep.
39:1693–1701. 2018.PubMed/NCBI
|
|
16
|
Zhao J, Geng L, Duan G, Xu W, Cheng Y,
Huang Z, Zhou Z and Gong S: REC8 inhibits EMT by downregulating
EGR1 in gastric cancer cells. Oncol Rep. 39:1583–1590.
2018.PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ceausu AR, Ciolofan A, Cimpean AM, Magheti
A, Mederle O and Raica M: The mesenchymal-epithelial and
epithelial-mesenchymal cellular plasticity of liver metastases with
digestive origin. Anticancer Res. 38:811–816. 2018.PubMed/NCBI
|
|
19
|
Chen D, Lin X, Zhang C, Liu Z, Chen Z, Li
Z, Wang J, Li B, Hu Y, Dong B, et al: Dual PI3K/mTOR inhibitor
BEZ235 as a promising therapeutic strategy against
paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR
pathway. Cell death Dis. 9:1232018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu J, Li Z, Su Q, Zhao J and Ma J: TRIM29
promotes progression of thyroid carcinoma via activating P13K/AKT
signaling pathway. Oncol Rep. 37:1555–1564. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiao C, Hong H, Yu H, Yuan J, Guo C, Cao H
and Li W: MiR-340 affects gastric cancer cell proliferation, cycle,
and apoptosis through regulating SOCS3/JAK-STAT signaling pathway.
Immunopharmacol Immunotoxicol. 40:278–283. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tan P, He L, Cui J, Qian C, Cao X, Lin M,
Zhu Q, Li Y, Xing C, Yu X, et al: Assembly of the WHIP-TRIM14-PPP6C
mitochondrial complex promotes RIG-I-mediated antiviral signaling.
Mol Cell. 68:293–307.e5. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jia X, Zhou H, Wu C, Wu Q, Ma S, Wei C,
Cao Y, Song J, Zhong H, Zhou Z and Wang J: The ubiquitin ligase
RNF125 targets innate immune adaptor protein TRIM14 for
ubiquitination and degradation. J Immunol. 198:4652–4658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang T, Ren Y, Liu R, Ma J, Shi Y, Zhang L
and Bu R: miR-195-5p suppresses the proliferation, migration, and
invasion of oral squamous cell carcinoma by targeting TRIM14.
Biomed Res Int. 2017:73781482017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu GH, Li AM, Li X, Yang Z and Peng H:
Bispecific antibody suppresses osteosarcoma aggressiveness through
regulation of NF-κB signaling pathway. Tumour Biol.
39:10104283177055722017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Z, Wang Y, Dou C, Sun L, Li Q, Wang L,
Xu Q, Yang W, Liu Q and Tu K: MicroRNA-1468 promotes tumor
progression by activating PPAR-γ-mediated AKT signaling in human
hepatocellular carcinoma. J Exp Clin Cancer Res. 37:492018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Z, Dou C, Yao B, Xu M, Ding L, Wang Y,
Jia Y, Li Q, Zhang H, Tu K, et al: Ftx non coding RNA-derived
miR-545 promotes cell proliferation by targeting RIG-I in
hepatocellular carcinoma. Oncotarget. 7:25350–25365.
2016.PubMed/NCBI
|
